8th June 2025, During the 66th meeting of the Drugs Consultative Committee (DCC) held at CDSCO, New Delhi, a significant regulatory concern regarding the unauthorized issuance of manufacturing licenses for new drugs by certain State Licensing Authorities (SLAs) was deliberated. â ︅
Recent Post
- Schedule H2 Expanded: Antimicrobials and Many Other Drugs Now Under Stricter Controls
- CDSCO Restricts IVF Supplies to Registered ART Centres
- CDSCO Issues Clarity on New Drugs, DC Granules & MR Pellets Licensing
- Centre Bans 16 Fixed Dose Combinations Under Section 26A of Drugs & Cosmetics Act
- India Cracks Down on Chloramphenicol & Nitrofurans in Food Producing Animals
